Clinical Trial
Study Details
HQK-1001 tablets, once daily for daily 26 weeks
The purpose of this study is to evaluate the safety and tolerability of three dose levels of HQK-1001 administered once daily for 26 weeks in subjects with sickle cell disease.
Study Overview
Contacts and Locations
Children's Hospital and Research Center - Oakland
Oakland, California 94609
United States
University of Miami Miller School of Medicine - Dept of Pediatrics
Miami, Florida 33101
United States
Georgia Health Sciences University - Adult SIckle Cell Center
Augusta, Georgia 30912
United States
University of Illinois at Chicago - Dept of Pediatrics
Chicago, Illinois 60612
United States
LSU Health Sciences Center - Feist Weiller Cancer Center
Shreveport, Louisiana 71103
United States
Tufts Medical Center
Boston, Massachusetts 02111
United States
University of North Carolina at Chapel Hill - Comprehensive Sickle Cell Program
Chapel Hill, North Carolina 27599
United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio 45229
United States
Univerisity of Texas Southwestern Medical Center at Dallas - Pediatric Hematology Oncology
Dallas, Texas 75390-9063
United States
The Hospital for Sick Children
Toronto Ontario MSG 1X8
Canada
University Health Network Toronto General Hospital
Toronto Ontario MSG 2C4
Canada
Abu El Reesh Pediatric University Hospital
Cairo
Egypt
University of the West Indies - Sickle Cell Unit
Mona
Kingston
Jamaica
American University of Beirut Medical Center
Beirut
Lebanon
Rafik Hariri University Hospital
Beirut
Lebanon
Chronic Care Center
Hazmiyeh
Lebanon